Global Acute Renal Failure (ARF) Market, By Type (Prerenal, Intrarenal, Postrenal), Diagnosis (CT Scan, Kidney Biopsy, Ultrasound), Treatment (Medications and Dialysis), Route of Administration (Oral, Parenteral, Others), End-Users (Clinics, Hospitals, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Acute Renal Failure (ARF) Market
Acute renal failure (ARF) market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 5.10% in the above-mentioned research forecast period. Rising geriatric population and increasing burden of acute renal failure among others.
Rising obese and diabetic population and increasing incidence of dengue, malaria and leptospirosis also boost up the market growth. Moreover, increasing research and development, presence of pipeline drugs and rising healthcare expenditure act as opportunity for the market growth. But, sometimes adverse effect caused by medications, lack of caregiver coordination and strict regulatory framework for drug approval may hamper the global acute renal failure (ARF) market.
Acute renal failure (ARF) is characterized by the sudden loss of kidney ability to eliminate the excess of fluid, metabolic waste and salts from the body. This inability leads to accumulation of electrolytes and metabolic wastes in the body that leads to life-threatening issues. Acute kidney failure develops in less interval of time and has been reported mostly to affect the people who are already hospitalized especially in people who rely on intensive care. The most common symptom associated with ARF includes decrease urine output, fluid retention, fatigue, confusion, nausea, weakness, irregular heartbeat, chest pain, seizures among others. Primarily acute renal failure is prerenal, postrenal and intrarenal failure. Prerenal failure commonly arises due to depletion of intravascular volume, intrarenal arises due to tubules damage while postrenal is most commonly associated with obstruction of tracks. Moreover severe dehydration, autoimmune diseases, medication toxicity can also lead to ARF. Acute renal failure can be treated by balancing of body fluids, calcium supplements, potassium supplements and dialysis.
According to the publication of National Kidney Foundation Inc. over 2 million people worldwide receiving kidney associated disease treatment with either dialysis and kidney transplant. As the kidney affected people rising worldwide, they demands effective treatment and therapies hence expected to provide market with the lucrative growth.
This acute renal failure (ARF) market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Acute Renal Failure (ARF) Market Scope and Market Size
Acute renal failure (ARF) market is segmented on the basis of type, diagnosis, treatment, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the acute renal failure (ARF) market is segmented into prerenal, intrarenal, postrenal.
- On the basis of diagnosis, the acute renal failure (ARF) market is segmented into CT scan, kidney biopsy, ultrasound.
- On the basis of treatment, the acute renal failure (ARF) market is segmented into medications and dialysis. Medication segment is further sub-segmented into sodium bicarbonates, N-acetyl cysteine, statins, others.
- On the basis of end-users, the acute renal failure (ARF) market is segmented into clinics, hospitals, home healthcare, others.
- On the basis of distribution channel, the acute renal failure (ARF) market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others.
Acute renal failure (ARF) Market Country Level Analysis
Acute renal failure (ARF) market is analysed and market size information is provided by country, type, diagnosis, treatment, end-users and distribution channel as referenced above.
The countries covered in the Acute renal failure (ARF) market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share due to the high awareness among the patients regarding disease symptoms and its treatment options and presence of major market players. Europe accounts the second largest market share due to due to high penetration of market players by taking strategic initiatives for enhancing their distribution channel. Asia-Pacific is expected to account for the largest market share over coming years for the acute renal failure (ARF) market due to increasing demand of effective treatment solutions and rising patient population.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Acute renal failure (ARF) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Acute Renal Failure (ARF) Market Share Analysis
Acute renal failure (ARF) market competitive landscape provides details by competitor. details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Acute renal failure (ARF) market.
The major players covered in the Acute renal failure (ARF) market are Alloksys, Angion, Quark, AM-Pharma B.V., Atox Bio, Astellas Pharma Inc., Pharming, MediBeacon, Exponential Biotherapies, Sequens, Pfizer Inc., Solvay, Leisha Pharma Solutions Pvt. Ltd., Merck KGaA, Wacker Chemie AG, Hetero Healthcare Limited., Zydus Cadila, Dr. Reddy’s Laboratories, Novartis AG, Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceutical Inc among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-